Back to CVE records
Critical 9.8Published Aug 22, 2023
CVE-2022-45611An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.
Updated under an hour ago ()
Does this affect you?
It affects fresenius-kabi pharmahelp_firmware. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Start free and add your stack
Free account, 1 product
An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.
- CVSS
- 9.8 CRITICAL (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
- Weakness (CWE)
- Not given
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- mitre
- NVD analysis
- Modified
- Record last updated
- Nov 27, 2024
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
fresenius-kabi pharmahelp_firmware fresenius-kabi:pharmahelp_firmware | 5.1.759.0 | NVD |
References
- https://www.fresenius-kabi.com/de-at/produkte/pharmahelp-compounderproduct
- https://www.fresenius.com/sites/default/files/2023-11/Fresenius%20-%20CVE-2022-45611.pdf
- https://www.fresenius.com/sites/default/files/2023-12/Fresenius%20-%20CVE-2022-45611.pdf
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.